Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Confocal Laser Endomicroscopy as an IMaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

NCT ID: NCT03492151Sponsor: Ohio State University Comprehensive Cancer CenterLast updated: 2025-08-22

Summary

The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is also sent for molecular analysis. The results of the cyst fluid molecular analysis (B) will be utilized for the most likely diagnosis. Based on institutional multidisciplinary tumor board meetings, surgery is performed as indicated (C). Surgical histopathology serves as "gold standard" for diagnosis. It is anticipated that the majority of patients will undergo surgical resection after their EUS.

Outcome measures

Primary

  • Accuracy of PCL diagnosis

    Diagnostic accuracy of confocal laser endomicroscopy and/or cyst fluid molecular markers and/or composite clinical and imaging features for the diagnosis of mucinous PCLs, PCLs with malignant potential, specific PCL types, and mucinous PCLs with advanced neoplasia.

    Time frame: 48 months

  • Accuracy of risk-stratification of IPMNs

    Diagnostic accuracy of confocal laser endomicroscopy and/or composite clinical and imaging features for the risk stratification of IPMNs

    Time frame: 48 months

Secondary

  • Imaging quality

    Time frame: 48 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Patient age 18 years or older * All patients referred for EUS-FNA of accessible PCL where surgery is contemplated * Minimum cyst size should be ≥ 2.0 cm as determined by prior cross-sectional imaging studies Exclusion Criteria: * Unable to obtain informed consent * Unable to tolerate the procedure * Women with known pregnancy at time of procedure * Patient age less than 18 years * Bleeding diathesis * Known allergy to fluorescein * Prior pancreatic cancer * Prior pancreatic surgery

Study locations (10)

Mayo Clinic Scottsdale Campus

Scottsdale, Arizona, 85259

Recruiting
Veronica Oria · Contact
Rahul Pannala · Principal Investigator

Stanford Hospital

Stanford, California, 94305

Recruiting
Samer El-Dika · Contact
Samer El-Dika · Principal Investigator

Yale School of Medicine

New Haven, Connecticut, 06510

Recruiting
Chloe Bennett · Contact
Thiruvengadam Muniraj, MD, MRCP · Principal Investigator

Parkview Hospital Randallia

Fort Wayne, Indiana, 46805

Active Not Recruiting

The Johns Hopkins Hospital

Baltimore, Maryland, 21287

Recruiting
Kylie Ning · Contact
Anne Marie Lennon · Principal Investigator

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215

Recruiting
Roya Dastjerdi, MPH · Contact
Mandeep Sawhney, MD · Principal Investigator

NYU Langone Health

Garden City, New York, 11530

Recruiting
Maria Marotta-Kollarus · Contact
Jessica Widmer, MD · Sub Investigator
Tomas Gonda, MD · Principal Investigator

Icahn School of Medicine at Mount Sinai

New York, New York, 10029

Recruiting
Sharon Slomovich · Contact
Frank Gress, MD · Principal Investigator

The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210

Recruiting

Baylor College of Medicine

Houston, Texas, 77030

Recruiting
Chandra Kovvali · Contact
Mohamed Othman, MD · Principal Investigator

References

  • Firkins SA, Chen W, Krishna SG. Morphologic and Microscopic Characterization of an Unusual Pancreatic Cystic Lesion. Gastroenterology. 2021 May;160(6):e14-e16. doi: 10.1053/j.gastro.2020.09.046. Epub 2020 Oct 8. No abstract available.(PubMed)